tiprankstipranks
Advertisement
Advertisement

AKBA Stock Latest News

Akebia Therapeutics Earnings Call: Vafseo Drives Growth
Company AnnouncementsAkebia Therapeutics Earnings Call: Vafseo Drives Growth
27d ago
AKBA
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
1M ago
AKBA
BDSX
Akebia reports Q4 EPS (5c), consensus (4c)
PremiumThe Fly
Akebia reports Q4 EPS (5c), consensus (4c)
1M ago
AKBA
Akebia price target lowered to $4 from $5 at BTIG
PremiumThe Fly
Akebia price target lowered to $4 from $5 at BTIG
1M ago
AKBA
Akebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Akebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
1M ago
AKBA
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
PremiumCompany AnnouncementsAkebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
2M ago
AKBA
Akebia price target lowered to $4 from $6 at Piper Sandler
Premium
The Fly
Akebia price target lowered to $4 from $6 at Piper Sandler
2M ago
AKBA
Akebia Therapeutics Updates Executive Severance and Leadership Terms
Premium
Company Announcements
Akebia Therapeutics Updates Executive Severance and Leadership Terms
2M ago
8K
AKBA
Akebia announces corporate updates, 2026 pipeline outlook
PremiumThe Fly
Akebia announces corporate updates, 2026 pipeline outlook
3M ago
AKBA
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
PremiumCompany Announcements
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
3M ago
8K
AKBA
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
PremiumRatings
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
3M ago
AKBA
Akebia announces first patient dosed in Phase 2 trial of praliciguat
PremiumThe Fly
Akebia announces first patient dosed in Phase 2 trial of praliciguat
3M ago
AKBA
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
PremiumRatingsStrategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
4M ago
AKBA
Akebia Therapeutics Acquires Global Rights to ADX-097
Premium
Company Announcements
Akebia Therapeutics Acquires Global Rights to ADX-097
4M ago
8K
AKBA
Akebia Therapeutics announces establishment of rare kidney disease pipeline
Premium
The Fly
Akebia Therapeutics announces establishment of rare kidney disease pipeline
4M ago
AKBA
QTTB
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
PremiumThe Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
4M ago
AKBA
QTTB
Q32 Bio sells complement inhibitor ADX-097 to Akebia
PremiumThe Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia
4M ago
AKBA
QTTB
Akebia Therapeutics Amends License Agreement with MEDICE
PremiumCompany Announcements
Akebia Therapeutics Amends License Agreement with MEDICE
5M ago
8K
AKBA
Akebia Therapeutics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Akebia Therapeutics’ Earnings Call: Growth Amid Challenges
5M ago
AKBA
Akebia Therapeutics Reports Strong Q3 2025 Growth
PremiumCompany AnnouncementsAkebia Therapeutics Reports Strong Q3 2025 Growth
5M ago
AKBA
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
Premium
The Fly
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
5M ago
JD
CNC
Akebia reports Q3 EPS 0c vs (10c) last year
Premium
The Fly
Akebia reports Q3 EPS 0c vs (10c) last year
5M ago
AKBA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >